title: Facilitating Antibacterial Drug Development in a Time of Great Need.
abstract: The continued development of new antibacterial drugs is critical to meet patient and public health needs. In this editorial, authors from the US Food and Drug Administration and European Medicines Agency reflect on the role of public-private partnerships and the development of clinical trials networks as agents to guide and perform quality studies of antibacterial drugs.
authors.affiliation: US Food and Drug Administration, Silver Spring, Maryland;
authors.forename: Edward
authors.initials: E
authors.lastname: Cox
authors.affiliation: European Medicines Agency, London, United Kingdom.
authors.forename: Marco
authors.initials: M
authors.lastname: Cavaleri
authors.affiliation: European Medicines Agency, London, United Kingdom.
authors.forename: Hans-Georg
authors.initials: HG
authors.lastname: Eichler
authors.affiliation: US Food and Drug Administration, Silver Spring, Maryland;
authors.forename: Janet
authors.initials: J
authors.lastname: Woodcock
authors.affiliation: US Food and Drug Administration, Silver Spring, Maryland;
authors.forename: Luciana
authors.initials: L
authors.lastname: Borio
mesh_terms: D000900:Anti-Bacterial Agents; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D006801:Humans; D055818:Public-Private Sector Partnerships
chemical_list: D000900:Anti-Bacterial Agents
keywords: antibacterial drug; development; public health